GeLongHui, November 27th | zhejiang hisoar pharmaceutical (002099.SZ) stated in recent investor relations activities that the company's polypeptide platform project has successfully entered the original drug enterprise supporting industry chain and achieved partial commercial supply of products. The company will continue to expand new project verification cooperation, promote domestic and foreign collaborations with other pharmaceutical companies, and increase product market share.
海翔药业(002099.SZ)：多肽平台项目已成功切入原研药企配套产业链并实现部分产品商业化供货
Zhejiang hisoar pharmaceutical (002099.SZ): The peptide platform project has successfully integrated into the industry chain supporting original research pharmaceutical companies and has achieved partial product commercialization supply.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated